TheBodyPro: Expert analysis from Benjamin Young, M.D., Ph.D.
Heavily treatment-experienced people with HIV are often overlooked in many areas of clinical science and drug development. In the U.S. these days, there are few enough of these people — and their individual cases are often unique enough — that it can be difficult to get resources focused on them as a group.
But the development of coformulated bictegravir/lenacapavir marks a welcome departure in this area: The ARTISTRY trials are exploring the combination not only as a general switch option for virologically suppressed people with HIV, but also specifically as an option for older patients with complicated treatment histories. Newly published findings raise hopes that a new choice is on the horizon for these individuals.
Read the full analysis here.
Source : TheBodyPro
Related HIV and Co-Infections News
-
Infectious Disease Special Edition: Immunomodulators in patients living with HIV
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.